Synonyms: MK0752
Compound class:
Synthetic organic
Comment: MK-0752 is a γ-secretase [1] and Notch pathway inhibitor that was originally intended for the treatment of Alzheimer's disease, but was later redeployed for anti-tumour potential.
|
|
No information available. |
Summary of Clinical Use ![]() |
MK-0752 progressed to early stage clinical evaluation in a number of cancer types, but as of January 2021 there were no active trials on ClinicalTrials.gov. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00572182 | MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer | Phase 1 Interventional | Pediatric Brain Tumor Consortium | Merck discontinued support for this study, so further accrual of participants was permanently stopped in 2011. | 3 |
NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) | Phase 1 Interventional | Merck Sharp & Dohme Corp. | ||
NCT01098344 | MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery | Phase 1 Interventional | Cancer Research UK | 2 |